Statin therapy to reduce disease progression from liver cirrhosis to cancer
Ended Awarded Last action
- Contract number
- HHSN26100012
- Awardee
-
Northwestern University UEI KG76WYENL5K1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $946,473
Award facts
- Contract value 100% obligated
- $946,472.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Chicago, IL 60611, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$46,035 | |
| Funding Only Action | -$28,546 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $162,356 | |
| Exercise an Option | $174,842 | |
| Change Order | $57,440 | |
| Change Order | $0 | |
| Original award | $626,416 |
About this award
This is a federal contract award from the National Cancer Institute, part of the Department of Health and Human Services, to Northwestern University, a private research university, for a Cancer Prevention Agent Development Program project. The contract has a ceiling value of $946,472.83 and a period of performance ending August 31, 2023. The objective is to conduct a randomized, double-blind, placebo-controlled Phase II clinical trial examining the effects of simvastatin versus placebo on liver disease progression in patients with liver cirrhosis.
Northwestern University has subcontracted with several institutions, including the University of Puerto Rico Medical Sciences Campus, Cedars-Sinai Medical Center, and Georgetown University, to support various aspects of the clinical trial. The award does not have a set-aside designation. This contract is part of the larger Cancer Prevention Agent Development Program 2012-2017, an initiative focused on early-phase clinical research to develop new cancer prevention agents.
Quick answers
Who was awarded contract HHSN26100012?
HHSN26100012 was awarded to Northwestern University by National Cancer Institute (National Institutes of Health) on September 15, 2016.
How much is contract HHSN26100012 worth?
The government has obligated $946,473 on HHSN26100012.
Is contract HHSN26100012 an order under another contract?
Yes. HHSN26100012 is a delivery order under HHSN261201200035I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100012 competed?
The extent of competition for HHSN26100012 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award